About the event

Held over a weekend, the event is structured around a series of exhibitions, workshops, and panel discussions. The exhibitions showcase a curated selection of photographs that tell compelling stories from various corners of the globe, each image accompanied by detailed narratives that provide context and deeper insight into the historical significance of the scenes depicted. These photographs are drawn from the archives of renowned photographers, as well as emerging talents, ensuring a blend of both classical and contemporary perspectives.

Cliff Palace, Colorado
Spruce Biosciences Inc (SPRB)’s Day in Review: Closing at 110.0, Up by 5.19 – DwinneX

Spruce Biosciences Inc (SPRB)’s Day in Review: Closing at 110.0, Up by 5.19

Ulysses Smith

Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.

After finishing at $104.57 in the prior trading day, Spruce Biosciences Inc (NASDAQ: SPRB) closed at $110.0, up 5.19%. In other words, the price has increased by $5.19 from its previous closing price. On the day, 54254.0 shares were traded. SPRB stock price reached its highest trading level at $110.0 during the session, while it also had its lowest trading level at $105.0.

Ratios:

Our goal is to gain a better understanding of SPRB by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.54 and its Current Ratio is at 1.54. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.09.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 06 ’25 when Parkman Healthcare Partners LL bought 256 shares for $17.91 per share. The transaction valued at 4,585 led to the insider holds 1,307 shares of the business.

Parkman Healthcare Partners LL sold 257 shares of SPRB for $4,920 on Oct 06 ’25. The 10% Owner now owns 1,050 shares after completing the transaction at $19.14 per share. On Oct 06 ’25, another insider, Parkman Healthcare Partners LL, who serves as the 10% Owner of the company, bought 256 shares for $17.91 each. As a result, the insider paid 4,585 and bolstered with 1,307 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SPRB now has a Market Capitalization of 117740704 and an Enterprise Value of 108419696. For the stock, the TTM Price-to-Sale (P/S) ratio is 168.20 while its Price-to-Book (P/B) ratio in mrq is 11.51. Its current Enterprise Value per Revenue stands at 155.552 whereas that against EBITDA is -2.192.

Stock Price History:

The Beta on a monthly basis for SPRB is 3.52, which has changed by -0.9660142 over the last 52 weeks, in comparison to a change of 0.12159383 over the same period for the S&P500. Over the past 52 weeks, SPRB has reached a high of $240.00, while it has fallen to a 52-week low of $4.28. The 50-Day Moving Average of the stock is 10.25%, while the 200-Day Moving Average is calculated to be 220.83%.

Shares Statistics:

The stock has traded on average 533.64K shares per day over the past 3-months and 207740 shares per day over the last 10 days, according to various share statistics. A total of 1.07M shares are outstanding, with a floating share count of 1.07M. Insiders hold about 0.00% of the company’s shares, while institutions hold 33.76% stake in the company. Shares short for SPRB as of 1763078400 were 86921 with a Short Ratio of 0.16, compared to 1760486400 on 20500. Therefore, it implies a Short% of Shares Outstanding of 86921 and a Short% of Float of 8.1999995.

Earnings Estimates

Spruce Biosciences Inc (SPRB) is presently subject to a detailed evaluation by 1.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$6.72, with high estimates of -$6.72 and low estimates of -$6.72.

Analysts are recommending an EPS of between -$23.84 and -$23.84 for the fiscal current year, implying an average EPS of -$23.84. EPS for the following year is -$28.18, with 1.0 analysts recommending between -$28.18 and -$28.18.

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.